Verrica Pharmaceuticals Inc. announced that the Company?s lead product, YCANTH?, has received New Chemical Entity (?NCE?) Status and a listing in the Orange Book from the U.S. Food and Drug Administration (?FDA?), providing a minimum five years of regulatory exclusivity. Formally described as the Approved Drug Products with Therapeutic Equivalence Evaluations, the Orange Book is an FDA publication that provides a list of drugs approved as safe and effective and also serves as the regulatory resource for information on drug marketing availability, bioequivalence, drug substitution, and patent and exclusivity data.1 The Orange Book also lists patents covering those drugs, approved methods of their use, and regulatory exclusivities to which they may be entitled.